Great Point Partners
The principals of Great Point Partners have a long history of helping executives build successful health care companies.
Business Model:
Revenue: $6.2M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Great Point Partners Information
Geographic Data
Address: 165 Mason Street 3rd Floor
City: Greenwich
State: CT
Zip: 06830
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$422M
Social
Twitter
Linkedin
Crunchbase
Metrics
3,873,674Website Global Rank
3,209Website Monthly Traffic
Twitter Followers
Description
The principals of Great Point Partners have a long history of helping executives build successful health care companies. Their investment team is augmented by their CEO Advisory Board and Medical Advisory Board, members of whom are available to provide advice and assistance to their entrepreneurs and their portfolio companies.
Contact Phone:
+12039713300
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2011 | Cytovance Biologics | Venture Round | 22.5M |
| 9/2022 | iXCells Biotechnologies | Private Equity Round | - |
| 5/2018 | Clinical Supplies Management | Debt Financing | - |
| 7/2022 | Ephicacy | Private Equity Round | - |
| 5/2022 | JPA Health | Private Equity Round | - |
| 11/2007 | SGX Pharmaceuticals | Post-IPO Equity | 25M |
| 9/2021 | BioAtla | Post-IPO Equity | 0 |
| 9/2021 | Velentium | Venture Round | - |
| 1/2004 | Forbes Medi-Tech | Series A | 10.8M |
| 8/2012 | Connecture | Venture Round | 20M |
| 6/2019 | Bionova Scientific | Private Equity Round | - |
| 2/2014 | Aurinia Pharmaceuticals | Post-IPO Equity | 52M |
| 5/2021 | Magenta Therapeutics | Post-IPO Equity | 86.4M |
| 10/2018 | Nebula Genomics | Series A | 0 |
| 9/2022 | Ventyx Biosciences | Post-IPO Equity | 0 |
| 10/2009 | Threshold Pharmaceuticals | Post-IPO Equity | 35M |
| 9/2008 | APT Pharmaceuticals | Series B | 32M |
| 2/2021 | Silence Therapeutics | Post-IPO Equity | 0 |
| 2/2023 | Abivax | Post-IPO Equity | 0 |
| 5/2019 | Axiom Real-Time Metrics | Private Equity Round | - |
| 3/2010 | BioSante Pharmaceuticals | Post-IPO Equity | 18M |
| 5/2011 | Biodel | Post-IPO Equity | 30M |
| 11/2011 | Aris Radiology | Private Equity Round | - |
| 11/2013 | Ocera Therapeutics | Post-IPO Equity | 0 |
| 11/2013 | Health Revenue Assurance Holdings | Venture Round | 5.4M |
| 1/2010 | Solta Medical | Post-IPO Equity | 17.2M |
| 5/2011 | WaferGen Biosystems | Post-IPO Equity | 0 |
| 12/2013 | Bovie Medical | Post-IPO Equity | 7M |
| 12/2004 | Panacos Pharmaceuticals | Post-IPO Equity | 20M |
| 10/2022 | Immunic Therapeutics | Post-IPO Equity | 60M |
| 3/2010 | Solta Medical | Post-IPO Equity | 4.8M |
| 6/2013 | iVantage Health Analytics | Private Equity Round | 10M |
| 10/2007 | APT Pharmaceuticals | Series A | 22M |
| 8/2022 | Heron Therapeutics | Post-IPO Equity | 76.5M |
| 8/2008 | Biotronic NeuroNetwork | Private Equity Round | - |
| 7/2022 | Ephicacy | Private Equity Round | - |
| 5/2022 | JPA Health | Private Equity Round | - |
| 9/2021 | Velentium | Venture Round | - |
| 9/2021 | BioAtla | Post-IPO Equity | 0 |
| 5/2021 | Magenta Therapeutics | Post-IPO Equity | 0 |
| 2/2021 | Silence Therapeutics | Post-IPO Equity | 0 |
| 6/2019 | Bionova Scientific | Private Equity Round | - |
| 5/2019 | Axiom Real-Time Metrics | Private Equity Round | - |
| 10/2018 | Nebula Genomics | Series A | 0 |
| 5/2018 | Clinical Supplies Management | Debt Financing | - |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
